<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53777">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02077231</url>
  </required_header>
  <id_info>
    <org_study_id>GlaucomaVitaminA</org_study_id>
    <nct_id>NCT02077231</nct_id>
  </id_info>
  <brief_title>Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaodong Zhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jinshan Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of the patients under long application of anti-glaucoma eyedrops endure severe ocular
      surface irritation, which interrupt their quality of life a lot. Lots of studies aimed to
      search for new drugs for therapy. The investigators hypothesized that the artificial tears
      containing vitamin A or carbomer may be a great substitute. Both of the two drugs were in
      common use and had already been tested in animals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change of the density of conjunctival goblet cells</measure>
    <time_frame>change from Baseline in goblet cell density at 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>tear film parameters changes in patients</measure>
    <time_frame>change from baseline in TBUT and Schirmer test at 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of ocular irritation in patients</measure>
    <time_frame>change from baseline in OSDI scores at 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>vitamin A palmitate eye gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1% vitamin A palmitate; Sinqi, Shenyang, China</description>
  </arm_group>
  <arm_group>
    <arm_group_label>carbomer eye gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2% Carbomer 940; Bausch &amp; Lomb, Aschheim, Germany</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin A</intervention_name>
    <description>use one drop in the eye</description>
    <arm_group_label>vitamin A palmitate eye gel</arm_group_label>
    <other_name>vitamin A palmitate eye gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carbomer eye gel</intervention_name>
    <description>use one drop in the eye</description>
    <arm_group_label>carbomer eye gel</arm_group_label>
    <other_name>Carbomer Eye Drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - diagnosed primary open-angle glaucoma or normal tension glaucoma patients with
        prostaglandin analogs treatment for more than one year.

        Exclusion Criteria:

          1. any systemic diseases which may cause ocular damage;

          2. previous ocular trauma or surgery;

          3. contact lens wear history in previous 6 months;

          4. application of any artificial tears 3 months ago;

          5. allergic to any of the drugs we used during examination.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>February 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jinshan Hospital</investigator_affiliation>
    <investigator_full_name>Xiaodong Zhou</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
    <mesh_term>Carbopol 940</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
